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Defects, as determined by Genome-Wide Association Studies (GWAS), in the complement 22 
cascade of innate immunity have been suggested to play a key role in Alzheimer’s disease 23 
(AD). These defective genes encode complement sub-component 1s (C1s), complement 24 
receptor 1, complement component 9, and clusterin, a fluid-phase regulatory protein. A 25 
dysregulated complement cascade has been shown to relate to poor cell activation, defective 26 
complement mediated clearance  and possible cognitive decline in AD patients. 27 
Porphyromonas gingivalis, a putative keystone pathogen of periodontal disease, has been 28 
reported to be associated with human AD brains of humans. The inflammatory burden 29 
following an experimental oral infection in mice and putative entry of this bacterium into the 30 
brain appears to drive the formation of amyloid-beta plaques and neurofibrillary tangles, 31 
followed by thewith loss of cognition. P. gingivalis is a master of immune subversion in this 32 
inflammatory cascade and may establish microbial dysbiosis where it is located. Here we 33 
discuss if P. gingivalis may enhance the detrimental effects of the defective GWAS 34 
complement cascade protein genes thereby contributing to formation of hallmark lesions of 35 
AD and excessive chronic inflammation and hallmark pathology in AD. It appears that P. 36 
gingivalis may rather emulate regulate genes involved in epigenetic mechanisms of AD by its 37 
LPS with little effect onand not defective genes in the complement system. 38 
 39 
KEYWORDS 40 
GWAS, periodontitis, P. gingivalis, immune subversion, complement, dysbiosis    41 
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Alzheimer’s disease (AD) is a neurodegenerative disease and the most common form of 43 
dementia. It differs from other forms of dementia by the presence of two hallmark proteins, 44 
amyloid-beta (Aβ) plaques and hyperphosphorylated tau bound to neurofibrillary tangles 45 
(NFTs). The cause of AD remains largely undefined. It is widely accepted that this complex 46 
neurological condition can co-exist with other complex diseases such as atherosclerosis and 47 
cerebrovascular /ischemic stroke [1-5]. The link with complex diseases is the apolipoprotein 48 
E gene allele 4 (APOE є4) inheritance [6-8]. The consequence of the APOE є4 inheritance is 49 
inappropriate defective complement activity [9, 10] because this isoform resists the innate 50 
immune cascade checkpoint control at C1q which is a subcomponent of the complement C1 51 
complex. [8]. Sustained complement activation is a potent driver of inflammation in the body 52 
including the brain [11-15]. Moreover, the abundant hallmark pathological lesions (Aβ 53 
plaques and NFTs), microbial pathogens, and physical injury can activate this innate immune 54 
cascade extracellularly as depicted by Aβ and/or intracellularly as per NFT bearing neurons 55 
[11-15]. Thius effectively makes it impossible to , it is not possible to disregard an 56 
inappropriate  unresolveddefective complement pathway activity in AD. 57 
Over the years several pathogens of bacterial, viral and fungal origin have been shown 58 
to be associated with AD brains [16]. The variability of the these microbes has significantly 59 
hampered the focus elucidation of their However, the etiologic role of these microbes in AD 60 
pathogenesis is still in question.  have raised the raising questions as to whether each of them 61 
species must should be considered a cause or result of inflammation in the AD brain.ative agent 62 
or if the ensuing brain inflammation they mau causeunifies their role. Recent studies have 63 
proposed that the putative keystone periodontal pathogen Porphyromonas gingivalis can be a 64 
risk factor that contributes to AD development in some individuals [17]. Periodontitis is a 65 
chronic inflammatory disease affecting the tooth supporting tissues, caused by a polymicrobial 66 
dysbiosis [18, 19]. It has been proposed that imbalance in complement activity may influence 67 
dysbiosis of host microbiomes [20]. Pathogens adopt and adapt to survival and utilization of 68 
longstanding inflammatory environments as demonstrated by the presence of P. gingivalis in 69 
the subgingival crevice (as commensal and pathogen) and at distant sites (heart, placenta, and 70 
perhaps brain) with inflammatory components for the development of systemic diseases [21].   71 
Aβ plaques and NFTs have been detected in brains of mice with the sporadic form of 72 
AD after infection with P. gingivalis [22]. Dominy et al. [17] showed that the enzymes 73 
gingipains produced by P. gingivalis can degrade the Tau protein, which is involved in NFT 74 
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formation in AD. In mouse brains, these lesions, purported entry of P. gingivalis, 75 
complement activation and APOE gene knock-out, all of which can accompany intracerebral 76 
inflammation [22, 23]. The recognized innate immune subversion caused by P. gingivalis, the 77 
antimicrobial protection hypothesis for lesions [24], and genetic polymorphisms in some 78 
complement genes [25-28] have relevance towards a basis for unresolved complement 79 
imbalance in AD. Lamont et al. [29] proposed that longstanding inflammatory conditions of 80 
the brain, typically AD, are related to growing old. During the lifespan of man there are 81 
changes both in the architecture such as an increased permeability in the blood-brain barrier 82 
(BBB) of the hippocampus [30], and functioning of the immune system (immunosenescence) 83 
[31]. The term immunosenescence refers to decline in fidelity and efficiency with age, 84 
resulting in an increased susceptibility to infectious diseases and pathological conditions 85 
relating to inflammation (e.g. cardiovascular disease and AD) or autoreactivity (e.g. 86 
rheumatoid arthritis) as described by Caruso et al. [32]. As an analogy to dysbiosis leading to 87 
periodontitis, tThis could perhaps promote the imflammophilic character of P. gingivalis in 88 
the old brain [31].  Therefore, P. gingivalis may becomes inflammophilic during advancing 89 
age.   90 
   91 
The complement system  92 
The complement system is comprised of more than 50 proteins, including the component 93 
proteins C1-C9, which are part of the innate immune system. There are regulatory proteins 94 
that serve to inhibit the complement cascade at various points [29]. The effector molecules 95 
(opsonins) illicit ongoing damage and initiate signaling cross-talk. Examples of membrane 96 
bound regulatory proteins include membrane cofactor protein (MCP or CD46), decay-97 
accelerating factor (DAF or CD55), complement receptor 1 (CR1 or CD35), and CD59. The 98 
soluble or fluid phase regulators, which form the focus of this review, are C4 binding protein 99 
(C4bp) and clusterin. Complement can be activated through the classical, alternative or lectin 100 
pathways [33]. An antibody bound to antigen or a solid surface can activate the classical 101 
pathway. Spontaneous hydrolysis of the complement protein C3 or binding of C3b to 102 
microbes activates the alternative pathway through the feedback loop, while mannose 103 
moieties on bacteria activate the lectin pathway [33-35]. All these pathways merge at the C3 104 
convertase (C4b2a) stage, which causes hydrolysis of C3 into C3a and C3b fragments [33], 105 
see Figure 1 and 2. While C3a is a potent anaphylatoxin that regulates immune responses 106 
such as inflammation in the fluid phase, C3b opsonizes target cells and promotes activation 107 
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of the terminal complement pathway, which ends with the assembly of the membrane attack 108 
complex (MAC) on target cells destined for killing [36]. All nucleated human cells can limit 109 
the lytic effect of the activated complement by expressing complement regulatory proteins 110 
[37]. However, gene polymorphisms may have major effects on the function of specific gene 111 
defects. Hence with polymorphic complement cascade genes identified in AD, we know little 112 
about their contribution to the overall effect on disease pathogenesis.  113 
 114 
Genome-Wide Association Studies link defects in the complement cascade 115 
with Alzheimer’s disease 116 
Genome-Wide Association Studies (GWAS) [25-28] reported the four defective genes that 117 
potentially link to AD progression: 1) complement sub-component 1s (C1s); 2) complement 118 
receptor 1; 3) complement component 9; and 4) clusterin, a fluid-phase regulatory protein. 119 
This is of concern because the brain, unlike other organs, is devoid of a traditional lymphatic 120 
vasculature system, meaning that an efficient complement cascade is critical for clearance of 121 
damaged cerebral tissue debris. Consequently, defective complement genes scattered within 122 
the early, middle and late stages of this cascade may be responsible for disabling the 123 
phagocytic activity of local microglia, resulting in inefficient removal of waste proteins such 124 
as Aβ and possibly “ghost” NFTs (tangles without cell surface membrane of the neuron) as 125 
typically seen in AD brains. An added complication of the AD brain is its association with 126 
microbes.  127 
Hence, the overall aim of this review is to discuss if the activated complement cascade 128 
in the presence of mutated complement components, together with P. gingivalis immune 129 
subversive properties, could possibly contribute to the severity, pathology, and progression of 130 
this neurodegenerative disease and result in common complement mediated chronic 131 
inflammatory activity.  132 
 133 
Complement proteins of polymorphic genes relevant to AD 134 
1) C1s 135 
C1s complexes with two molecules, C1r and C1q, and form C1 as the first component of the 136 
classical complement activation. C1 is a serine esterase that activates C4 and C2 thereby 137 
driving the classical pathway of complement activation [38]. C1 is not stable as it dissociates 138 
rapidly by the activity of the fluid phase regulator C1 inhibitor [39]. Interestingly, the 139 
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virulence associated gene 8 (Vag8) in Bordetella pertussis is a complement evasion molecule 140 
that mediates its effects by binding to the complement regulator C1 inhibitor (C1-INH), 141 
which is a fluid phase serine protease [40]. The absence of functional C1s (defected gene) 142 
suggests that C1 cannot be activated in the context of its ability to initiate the classical 143 
complement cascade [41]. In this scenario, the residentlocal microglial cells that express the 144 
phagocytic C1qR receptor [42] would fail in their function. However, if the C1s 145 
subcomponent is seen as an inactive protein, this could represent a pool of “inactivated” C1. 146 
“Inactivated” C1 can complex with C1r and C1q and activate the classical complement 147 
pathway initiate defective complement activation [41]. Literature supports inappropriate  148 
incomplete complement activation in AD brains [11-15]. This suggests that “inactivated” C1 149 
eventually binds to other “activators” (Aβ, NFTs, microbial pathogens, physical injury) 150 
which propagate the inappropriate incomplete complement pathway activity by cleaving the 151 
next component in the cascade in demented brains.  152 
 153 
2) CR1 154 
The GWAS support a CR1 gene defect in AD. This finding appears reasonable as AD 155 
patients have reduced resistance to infection by bacteria and viruses and yeasts that may 156 
promote development of AD [16]. In the context of bacterial infections for the pathogenesis 157 
of AD, prominence is being given to P. gingivalis [17, 23] that reaches the brain via the 158 
haematogenous route and Chlamydia-associated infections that are able to reach the brain via 159 
infected monocytes following increased BBB permeability [43]. The herpes simplex virus 160 
(HSV) type 1 [44] infections are endemic in the host and they become re-activated in some 161 
individuals leading to AD.  All the above listed infections associate with the Aβ hallmark 162 
lesion of AD [22, 45, 46], and both P. gingivalis infection and the HSV type I infection lead 163 
to cognitive deficit in mice [22, 46].  164 
and their neurons become severely compromised in both structure and function, as 165 
depicted by the Tau neurofibrillary tangle bearing cells typical of AD. CR1, also known as 166 
the C3b/C4b receptor, is a transmembrane glycoprotein that functions to inhibit activation of 167 
the C3/C5 convertase stage of the three converging activation pathways. Hence the location 168 
of CR1 in the complement cascade is pivotal to all subsequent effector pathways. CR1 helps 169 
to regulate activation of the complement cascade and promotes phagocytosis of cellular 170 
debris, as well as Aβ plaques, and adherence of immune complexes to erythrocytes. It has 171 
been demonstrated that the AD brain is generally deficient in CR1 [37]. Notably, it has been 172 
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reported that P. gingivalis infection mediates immune subversion in relation to CR1 [47]. 173 
Such observations reinforce regions of genetic weaknesses (as per CR1 gene defect, see [26]) 174 
that are also exploited in this case by P. gingivalis, albeit in a fully functional complement 175 
system.the overall immune mediated clearance of pathological and aggregated  176 
 177 
3) C9 178 
Complement component protein C9 is part of MAC, and its insertion into cell surface 179 
membranes induces pores to lyse target cells. Other than the GWAS, little is known about the 180 
deleterious effects of the defective C9 gene in relation to AD pathogenesis, or indeed in other 181 
complement deficiency related conditions. The earliest reports linking complement to Aβ 182 
plaques suggest that the activated complement cascade does not proceed to C9/MAC 183 
formation [48, 49]. Whether or not such an observation points to an underlying genetic defect 184 
in the C9 gene or incomplete activation of the complement cascade in presence of active 185 
genes remains to be clarified. However, if the defective C9 gene has lost its function, this 186 
may be one factor that can influence dysbiosis of the host’s oral/gut microbiomes as reported 187 
for AD [50]. One possibility is that the functional loss of complement activity (unable to kill 188 
the pathogen) would support the spread of microbes such as P. gingivalis in the body via 189 
increased permeability of the BBB in the elderlyold and the AD brains to circulating 190 
pathogensIn the context of a deregulated complement genes [14 because of incomplete 191 
activation of the complement cascade. Having established P. gingivalis colonization, the 192 
bacteria would dampen the proinflammatory activity of C5a by citrullination (discussed 193 
below). Thus, there remains a potential for a microbial component of AD brains that could 194 
promote rampant complement activation (due to gene deregulation) and the resulting 195 
excessive inflammation.  196 
 197 
4) Clusterin 198 
The polymorphism in the clusterin gene has a more convincing role in the pathogenesis of 199 
AD, relating to subtype (mild cognitive impairment and dementia), and the rate of 200 
progression [51-53]. It is one of the complement cascade regulatory plasma proteins that 201 
significantly increases during AD as compared with non-AD controls [54]. Clusterin also 202 
stimulates expression and secretion of various chemotactic cytokines, including tumor 203 
necrosis factor-alpha (TNF-α), which plays a critical role in promoting macrophage 204 
chemotaxis via the phosphoinositide 3-kinase/protein kinase B1 (Pi3K/Akt), mitogen-205 
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activated protein kinase/extracellular signal-regulated kinase (ERK) and c-Jun N-terminal 206 
kinase (JNK) pathways [55]. Pathogen-driven signaling pathways with kinases that 207 
phosphorylate proteins may also be involved in abnormal phosphorylation of Tau proteins, 208 
which are the major constituents of NFTs in AD. This possibility was illustrated by Ilievski et 209 
al. [22] who demonstrated ser396 phosphorylation following P. gingivalis oral infection in 210 
mice. Alternatively, gingipains can digest the normal Tau protein into fragments that may be 211 
toxic to neurons [17]. Further research should clarify the concomitant role of P. gingivalis 212 
and polymorphic complement genes in AD pathogenesis.  213 
 214 
The role of Aβ plaques and NFTs  in the classical complement pathway 215 
activation in AD 216 
The inflammatory component of AD was recognized through the classical complement 217 
pathway activation and receptors for specific (C3a, C5a) opsonins [11, 12, 56, 57]. Based on 218 
these early data, the fibrillary insoluble Aβ plaques were suggested to act as extracellular 219 
triggers of complement activation [58-61]. NFTs are intracellular triggers of complement 220 
activation via the classical pathway [62]. Building on the Dominy et al. [17] observation that 221 
gingipains degrade Tau protein could reveal new triggers of intracellular complement activity 222 
in AD brains. We now know that APOE є4 gene inheritance is less efficient in inhibiting 223 
complement activation at the C1q checkpoint and that it adds to further risk for complement 224 
mediated inflammation independent of Aβ [8]. Taken together with the GWAS identified 225 
complement gene defects, this strengthens the inflammatory hypothesis of AD via 226 
inappropriate  inadequate complement activity [11-15].  227 
  228 
Apolipoprotein E-C1q complexes as inhibitors of the activated classical 229 
complement pathway 230 
It is becoming clear that the APOE є4 susceptibility gene may be linked to deregulating C1q 231 
to keep the classical complement pathway activated [8]. This causes a dysregulated innate 232 
immune inflammatory response via cytokine liberation by activated 233 
monocytes/macrophages/microglia [63]. In the brain, the oxidized lipids also accumulate at 234 
the periphery of Aβ plaques [8], which leads to yet more inappropriate  inadequate activation 235 
of complement activity. The APOE є4 susceptibility gene is also linked with environmental 236 
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risk factors, including the host’s dysbiotic oral microbiome [64]. The sustained inflamed 237 
environment of the brain could act as an intrinsic environmental factor that supports 238 
dysbiosis. 239 
 240 
Synaptic loss: A potential consequence of activated complement cascade  241 
The phagocytic role in the brain is well-recognized as an arm of the complement cascade and 242 
generally regarded as being beneficial to the host. However, in AD brains activated 243 
complement CR1 helps to regulate and promote phagocytosis, in microglia, of the cellular 244 
debris. With the CR1 activity being suppressed (via the deregulated CR1 gene and immune 245 
evasion strategies of P. gingivalis) this would suggest accumulation of abnormal proteins. 246 
Although this is the case in AD, but an additional outcomeappears to appears to be theresult 247 
in excessive loss of synapses. This is supported by as interpreted from in vivo studies, 248 
whereby the classical complement pathway was activated via (oligomeric) Aβ and leading to 249 
excessive pruning of synapses by microglia [65]. Similarly, there remains a possibility for 250 
viral and P. gingivalis infections to contribute to synaptic loss via complement activation 251 
independently of Aβ [23, 5960, 6061].  252 
 253 
Concept of cognitive deterioration in AD 254 
Cognitive deterioration (difficulties in decision making and deteriorating mental function 255 
with changes in mood and behaviors) is an essential component of the clinical picture of AD. 256 
Exactly what causes functional loss in AD remains unknown. However, the original synaptic 257 
loss theory [66, 67] is still considered valid, as it continues to correlate with deteriorating 258 
memory. A question arises as if the mechanism of overt synaptic loss relates to an overactive 259 
complement cascade [65, 68]. Observational studies demonstrate that some very elderly 260 
subjects bypass AD, whilst harboring equivalent numbers of Aβ plaques and NFTs in their 261 
brains. This suggests that these lesions, per se, do not necessarily cause functional deficits. 262 
Such individuals have been termed as having a “cognitive reserve” [69, 70]. Another group of 263 
elderly patients’ brains have shown extensive numbers of Aβ plaques and NFTs without the 264 
individual receiving a diagnosis of clinical AD. These individuals have been referred to as 265 
having “resilient” brains [71]. The difference between those with cognitive reserve and 266 
resilient brains, over individuals with AD, is the absence of intracerebral inflammation [71]. 267 
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This observation emphasizes the role of chronic inflammation, in some individuals, for the 268 
functional loss.  269 
 270 
Microbial component in AD pathophysiology  271 
The studies carried out by Vasek et al. [68] supporting the role of complement activity via an 272 
initial infection causing overt pruning pruning loss of synapses and giving rise to clinical 273 
symptoms, can be explained through classical plaques. Research has linked Aβ to a broad-274 
spectrum antimicrobial peptide (AMP) [72-74]. If Aβ deposition represents the host’s 275 
response to a previous infection, then its role as an AMP is consistent with triggering 276 
complement activation [24, 73]. This forms a common link with the antimicrobial protection 277 
hypothesis [23], whereby the modality of Aβ’s pathophysiology is shifted towards a 278 
dysregulated innate immune response, and indirectly, with the microbial infection hypothesis 279 
and the amyloid cascade hypothesis [75]. The only difference is that that the amyloid 280 
hypothesis maintains that Aβ is toxic, whilst the antimicrobial protection hypothesis suggests 281 
AD pathology develops from a pattern of innate immune responses mounted by an immune 282 
challenge. 283 
P. gingivalis is an oral pathogen that has been used to develop models for periodontal 284 
infection and AD in mice [22, 23]. Most interestingly, the periodontal infection model of 285 
Ilievski et al. [22] has demonstrated detection of  Aβ and NFTs in mouse brains. Therefore, 286 
by example of in vivo bacterial infections, P. gingivalis gives rise to Aβ in the brain produced 287 
by the host with implication for pathogen to entrapment and killing it. This confirms that P. 288 
gingivalis can initiate Aβ and NFT formation and that this, over time, will contribute to the 289 
overall burden of hallmark AD lesions proteins (Figure 2). In addition, P. gingivalis activates 290 
complement in the absence of Aβ in the brain [23]. Complement activation following 291 
bacterial entry into the brain is to be expected, but this observation may also explain memory 292 
impairment possibly through intercommunication with toll-like receptor (TLR) activation, 293 
lipopolysaccharide (LPS) (a TLR4 agonist) and complement activation [49, 76-78]. 294 
Collectively, they may also cause overt pruning loss of synapses [5965, 6068] if CR1 295 
functionality is suppressed by its polymorphism or via immune evasion strategies of bacteria 296 
like P. gingivalis.  297 
 298 
P. gingivalis and its complement subversion 299 
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P. gingivalis has been shown to be a major manipulator of the immune system [79-84] and is 300 
considered a keystone pathogen in “chronic” periodontitis [85]. Furthermore, periodontitis 301 
has a clear relationship with late onset AD, which is the most common form of AD [86-90].  302 
 303 
Gingipains as players in immune subversion 304 
Gingipains are virulence factors of key importance to the immune subversion activity of P. 305 
gingivalis,. There arewhich has two main types of cysteine proteases [92] encoded by three 306 
different genes (rgpA, rgpB and kgp).: Of these the lysine specific gingipains is the product of 307 
kgp and the arginine specific gingipains rgpA and rgpB. These proteases can cleave the 308 
complement components C1-C5, prevent deposition of C3b on the bacterial surface and 309 
capture the C4b binding protein [93-97]. By hijacking binding to the complement regulator 310 
C4bp on the bacterial surface, P. gingivalis prevents assembly of the membrane attack 311 
complex and acquires the ability to regulate C3 convertase [95]. Thus, gingipains do not only 312 
destroy complement through proteolytic degradation, they also inhibit complement activation 313 
by binding to the complement inhibitor C4bp [95].  314 
If gingipains are involved in AD, they would likely enhance the effect of polymorphic 315 
complement gene defects, allowing for a local infection. Recruitment of additional bacteria 316 
that are resistant to the bactericidal activity of complement is also feasible [8894]. Besides, it 317 
is possible that gingipains, together with defective complement component genes, aggravate 318 
and sustain AD through ineffective clearance of cellular debris, which in turn, aids the 319 
accumulation of Aβ and NFTs. Tau protein that is associated with NFTs in AD brains is 320 
reported to be a substrate for gingipains [17]. Whether this is a strategy of P. gingivalis to 321 
keep complement activated or is independent of complement requires further research.   322 
 323 
P. gingivalis and citrullination in AD 324 
P. gingivalis can also reduce the antibacterial and proinflammatory activity of C5a by 325 
deiminating its C-terminal arginine [98]. Post-translational enzymatic modification of 326 
arginine residues in proteins formed as part of the complement cascade are some of the 327 
subversive physiological processes demonstrated by P. gingivalis. This offers a plausible and 328 
exclusive link to disabling complement C5a enzymatic conversion of arginine to citrulline. 329 
Protein citrullination causes deregulation of the host’s inflammatory signaling network by 330 
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altering the spatial arrangement of the original 3D-structure and function of immune proteins 331 
[99]. It is likely that degradation of complement proteins allows colonization and 332 
proliferation of bacteria possessing higher sensitivity towards complement mediated killing 333 
than found in P. gingivalis itself [82]. Accordingly, P. gingivalis may support survival of an 334 
inflammophilic biofilm community by helping bystander bacteria in the brain to evade 335 
complement-mediated killing. The concept of the brain possessing its own microbiome has 336 
not been fully explored and future studies will undoubtedly reveal whether alternative 337 
mechanisms exist for complement activation not proceeding to C9/MAC formation in AD 338 
[48, 49]. 339 
    340 
 341 
The presence of CR1 on peripheral blood cells, especially erythrocytes and macrophages, is 342 
abundant and suggestive of an important and significant role of CR1 in AD. For example, as 343 
a receptor for the components C3b and C4b, CR1 helps to regulate activation of the 344 
complement cascade and promotes phagocytosis of cellular debris, as well as Aβ and 345 
adherence of immune complexes to erythrocytes.  346 
Clusterin is a plasma protein that may play an important role in regulating C5b7-8 347 
stages of the terminal complement complex pathway, and in the subsequent pathogenesis of 348 
AD. The blood plasma analysis of APP/PS1 AD transgenic mice demonstrated greater 349 
concentration of clusterin, and an age-dependent upregulation in the brain, and its co-350 
localization with Aβ plaques [48, 51, 52]. Clusterin also stimulates expression and secretion 351 
of various chemotactic cytokines, including TNF-α, which plays a critical role in promoting 352 
macrophage chemotaxis, via the Pi3K/Akt, ERK and JNK pathways [55]. 353 
Data from GWAS suggest an involvement of CR1 and clusterin gene defects in AD 354 
[25-28]. Since P. gingivalis has the capacity to affect CR1 and clusterin, this strengthens the 355 
possible pathogenic role of this bacterium in AD, at least through increased immune 356 
subversive activity. For example, outside the brain, P. gingivalis was found to fix C3 and 357 
readily adhere to erythrocytes via CR1, and this led to a rapid degradation of C3 into iC3b, 358 
and presumably, C3dg on the erythrocyte cell surface [100].  359 
 360 
P. gingivalis and its possible subversion of C9 361 
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C9 is the ninth complement component protein, which is also a part of MAC.  Its insertion 362 
into cell surface membranes induces pores, causing lysis. P. gingivalis gingipains (Kgp, 363 
RgpA, and RgpB) degrade the central complement component C3. This prevents deposition 364 
of both C3b opsonin and MAC on P. gingivalis cells, by which the bacterium protects itself 365 
against complement [101]. It is known that the complement cascade does proceed to MAC 366 
formation in periodontitis, and this is due to the membrane bound regulator CD59 being 367 
partially effective. This allows for degradation of collagens and heme, which form essential 368 
nutrients for the bacterium. It tells us that the complement cascade is highly adaptable for 369 
exploitation by pathogens. Generalized gene defects are conducive to this exploitation, as 370 
reported by Kapferer-Seebacher et al. [96102] for the effects of C1S gene mutation in 371 
periodontitis in patients with Ehlers-Danlos syndrome. Such findings support sustained 372 
inflammation in periodontitis and AD brains, and the GWAS finding of the defective C9 gene 373 
causing deficiency in overall C9 protein synthesis, might primarily affect the brain.  374 
To date, there is only one report that tested complement activation in mouse brains. It 375 
confirmed entry of P. gingivalis [23] and demonstrated MAC on some neurons.  Although the 376 
difference from sham treated animals was not statistically significant, the data suggested that 377 
P. gingivalis may have the capacity to suppress the activity of C9 and impair MAC assembly 378 
via immune subversion.  379 
 380 
P. gingivalis and epigenetic modifications 381 
In the stimulation and maintenance of inflammation epigenetic pathways have received 382 
special attention because of their upstream regulations. Epigenetic modifications lead to 383 
chemical changes in DNA and associated proteins which cause remodeling of the chromatin 384 
and activation or inactivation of gene transcription. These changes can contribute to 385 
development and maintenance of cancer, autoimmune and inflammatory diseases, including 386 
periodontitis [103, 104]. Interestingly, knowledge of the modification of epigenetic 387 
mechanisms may provide insight into key regulatory pathways of genes involved in the 388 
maintenance of chronic inflammation. Thus, the role of DNA and histone modifications, 389 
which are major epigenetic regulations, have been described in periodontitis where gene 390 
expression can be affected by DNA methylation [105]. It has also been demonstrated that 391 
chronic inflammation in periodontitis may be linked with aberrant DNA methylation in the 392 
gingival tissues [106, 107]. In AD epigenetic mechanisms have been found to be 393 
dysregulated during disease progression, already in its early stages [108]. Furthermore, recent 394 
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methylome-wide association studies (MWAS) in humans have supported the concept that 395 
aberrant DNA methylation is associated with AD [109]. Whilst increased methylation in the 396 
gene promoter region is related to reduction in gene expression, hypomethylation is closely 397 
associated with transcriptional activation [110]. Recently, Diomede et al. [103] investigated if 398 
epigenetic modulations is involved in periodontitis by using human periodontal ligament 399 
stem cells (hPDLSCs) as an in vitro model. They found that P. gingivalis LPS significantly 400 
reduced DNA methylase DNMT1, while it markedly upregulated the level of histone 401 
acetyltransferase p300 and NF-kB in hPDLSCs. This demonstrated that P. gingivalis LPS 402 
markedly regulates genes involved in epigenetic mechanism, which may result in induction 403 
of inflammation locally and systemically. 404 
 405 
Molecular inhibitors as possible therapy in AD 406 
The emergence of complement as an important player in normal brain development and 407 
pathological remodeling has come as a major surprise to most neuroscientists and almost all 408 
of those working in the field of complement biology [23]. The role of inflammation in AD is 409 
well established. Interestingly, resolvin E1 and lipoxin A4 resolved the inflammation in a 410 
murine model of AD [111]. This leads to the question whether complement mediated therapy 411 
should also be considered to reduce the inflammatory load in AD and if so, when and how? 412 
Indeed, AD and periodontitis have complement-TLR intercommunication mediated 413 
inflammation in common. The contribution from peripheral sources to inflammatory 414 
mediators has an early impact on priming of intracerebral glial cells. An ideal window to 415 
control the impact of peripheral inflammation from periodontitis on AD would therefore 416 
appear to be from the time of diagnosis of the oral disease. The clinical value of inhibiting all 417 
the three main pathways of complement activation was recently suggested in periodontitis 418 
[112]. This can be achieved by targeting the central component C3, which directly inhibits 419 
inflammation and indirectly counteracts dysbiosis. By using a locally administered peptidic 420 
compound (Cp40/AMY-101), non-human primates were protected from induced and 421 
naturally occurring periodontitis (reference). This could pave the way for clinical trials for the 422 
treatment of human periodontitis and even for prevention of periodontitis in high risk 423 
patients, but this has not yet been tested in AD. 424 
 As for P. gingivalis, Dominy et al. [17] proposed that potent and selective gingipain 425 
inhibitors (Kgp) could be valuable for treating P. gingivalis colonization of the AD brain. 426 
Using effective molecular inhibitors of gingipains at later stages of this neurodegenerative 427 
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disease may be tried, but there are many causes of AD and multiple bacterial phylotypes 428 
discovered in demented brains. 429 
  430 
Concluding remarks 431 
There is no generally accepted view on the pathogenesis of AD, which is considered a 432 
multifactorial disease. Recent research has shown that an imbalaned complement system plays 433 
an important role in the AD brain. Whether nature provided this early immune system to be 434 
protective, as suggested by the Aβ-AMP concept, or other forms of toxicity in old age is a 435 
subject open to debate. By affecting some of the gene defective proteins, P. gingivalis may 436 
amplify complement mediated inflammatory dysbiosis, but this has tomust be proven.  437 
Now that the GWAS has demonstrated the role of defective complement activation in 438 
AD development, this supports our working hypothesis that AD in some patients is mediated 439 
by the host’s inflammatory responses and justifies the rationale for novel interventions to 440 
improve lifestyle, behavior and regular dental care. However, there is no definite proof yet of 441 
a link in AD between defects in the complement cascade of innate immunity and P. 442 
gingivalis. This bacterium could rather emulate genes involved in epigenetic mechanisms by 443 
its LPS, which may result in induction of inflammation locally and systemically. Future 444 
research should try to establish a better foundation for the notion that there could be a genetic 445 
basis for P. gingivalis infection in AD.  446 
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Figure 1. Illustration showing the effects of P. gingivalis oral infection and its local 742 
subversive effect on degradation of opsonins with IgG, C1q, iC3b and MAC to evade 743 
complement mediated death and at the same time amplify inflammation. In the brain, a nerve 744 
cell infected by P. gingivalis itself or internalization of outer membrane vesicles 745 
(microbullets) initiate microglial surveillance. This results in an inflammatory activity when 746 
the host cell encounters Aβ (in its capacity as an AMP) opsonized by IgG, C3b and iC3b 747 
opsonins in the paths of the neuronal processes. Due to polymorphic defects in the 748 
complement regulating proteins, and the inability of microglia to clear Aβ, inflammation is 749 




Figure 2. A “frustrated innate immune system” in the inflamed Alzheimer’s disease brain. 752 
This contribution is from multiple sources including .the  Polymorphic complement 753 
component genes [26, 27, 28];, APOE variant [8]; , blood-brain barrier defects [30];, 754 
pathogen entry, and Aβ as a defence peptide released in response to infections [24]. All these 755 
contribute to complement activity, reduced cell activation, defective phagocytosis and 756 
chronic inflammation [15]. There would be clinical value in inhibiting all three main 757 
pathways of complement at the C3 stage.. Hope lies in the peptidic compound (Cp40/AMY-758 
10) [105], gingipains inhibitors (COR388) [16] and better oral hygiene [106]. 759 
 760 
